Inmaculada Domínguez

Inmaculada Domínguez

Auto-generated profile, based on publicly available information

Inmaculada Domínguez

Department of Cell Biology, Faculty of Biology, University of Seville, Avda. Reina Mercedes 6, 41012 Seville, Spain

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in International Journal of Radiation Biology
Verified
Journal Article
Open access
UOUrsula Oestreicher
Ursula Oestreicher
DSDaniel Samaga
Daniel Samaga
EAElizabeth Ainsbury
Elizabeth Ainsbury
AAAna Catarina Antunes
Ana Catarina Antunes
ABAns Baeyens
Ans Baeyens
AWAndrzej Wojcik
Andrzej Wojcik
Purpose: Two quality controlled inter-laboratory exercises were organized within the EU project ‘Realizing the European Network of Biodosimetry (RENEB)’ to further optimize the dicentric chromosome assay (DCA) and to identify needs for training and harmonization activities within the RENEB network. Materials and methods: The general study design included blood shipment, sample processing, analysis of chromosome aberrations and radiation dose assessment. After manual scoring of dicentric chromosomes in different cell numbers dose estimations and corresponding 95% confidence intervals were submitted by the participants. Results: The shipment of blood samples to the partners in the European Community (EU) were performed successfully. Outside the EU unacceptable delays occurred. The results of the dose estimation demonstrate a very successful classification of the blood samples in medically relevant groups. In comparison to the 1st exercise the 2nd intercomparison showed an improvement in the accuracy of dose estimations especially for the high dose point. Conclusions: In case of a large-scale radiological incident, the pooling of ressources by networks can enhance the rapid classification of individuals in medically relevant treatment groups based on the DCA. The performance of the RENEB network as a whole has clearly benefited from harmonization processes and specific training activities for the network partners.

22 April 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MOManuel Luís Orta
Manuel Luís Orta
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
IDInmaculada Domínguez
Inmaculada Domínguez
NPNuria Pastor
Nuria Pastor
EBEstefanía Burgos
Estefanía Burgos
THThomas Helleday
Thomas Helleday
5-Aza-2′-deoxycytidine (5-azadC) is a DNA methyltransferase (DNMT) inhibitor increasingly used in treatments of hematological diseases and works by being incorporated into DNA and trapping DNMT. It is unclear what DNA lesions are caused by 5-azadC and if such are substrates for DNA repair. Here, we identify that 5-azadC induces DNA damage as measured by γ-H2AX and 53BP1 foci. Furthermore, 5-azadC induces radial chromosomes and chromatid breaks that depend on active replication, which altogether suggest that trapped DNMT collapses oncoming replication forks into double-strand breaks. We demonstrate that RAD51-mediated homologous recombination (HR) is activated to repair 5-azadC collapsed replication forks. Fanconi anemia (FA) is a rare autosomal recessive disorder, and deaths are often associated with leukemia. Here, we show that FANCG -deficient cells fail to trigger HR-mediated repair of 5-azadC-induced lesions, leading to accumulation of chromatid breaks and inter-chromosomal radial fusions as well as hypersensitivity to the cytotoxic effects of 5-azadC. These data demonstrate that the FA pathway is important to protect from 5-azadC-induced toxicity. Altogether, our data demonstrate that cytotoxicity of the epigenetic drug 5-azadC can, at least in part, be explained by collapsed replication forks requiring FA-mediated HR for repair.

29 July 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MOManuel Luís Orta
Manuel Luís Orta
AHAndreas Höglund
Andreas Höglund
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
IDInmaculada Domínguez
Inmaculada Domínguez
EBEstefanía Burgos
Estefanía Burgos
THThomas Helleday
Thomas Helleday
Decitabine (5-aza-2′-deoxycytidine, 5-azadC) is used in the treatment of Myelodysplatic syndrome (MDS) and Acute Myeloid Leukemia (AML). Its mechanism of action is thought to involve reactivation of genes implicated in differentiation and transformation, as well as induction of DNA damage by trapping DNA methyltranferases (DNMT) to DNA. We demonstrate for the first time that base excision repair (BER) recognizes 5-azadC-induced lesions in DNA and mediates repair. We find that BER (XRCC1) deficient cells are sensitive to 5-azadC and display an increased amount of DNA single- and double-strand breaks. The XRCC1 protein co-localizes with DNMT1 foci after 5-azadC treatment, suggesting a novel and specific role of XRCC1 in the repair of trapped DNMT1. 5-azadC-induced DNMT foci persist in XRCC1 defective cells, demonstrating a role for XRCC1 in repair of 5-azadC-induced DNA lesions. Poly (ADP-ribose) polymerase (PARP) inhibition prevents XRCC1 relocation to DNA damage sites, disrupts XRCC1–DNMT1 co-localization and thereby efficient BER. In a panel of AML cell lines, combining 5-azadC and Olaparib cause synthetic lethality. These data suggest that PARP inhibitors can be used in combination with 5-azadC to improve treatment of MDS and AML.

1 January 2003 in Mutation Research - Reviews in Mutation Research
Verified
Journal Article
Closed access
FCFelipe Cortés
Felipe Cortés
NPNuria Pastor
Nuria Pastor
SMSantiago Mateos
Santiago Mateos
IDInmaculada Domı́nguez
Inmaculada Domı́nguez

6 October 2016 in International Journal of Radiation Biology
Verified
Journal Article
Open access
UKUlrike Kulka
Ulrike Kulka
MAMichael Abend
Michael Abend
EAElizabeth Ainsbury
Elizabeth Ainsbury
Christophe BadieChristophe Badie
Christophe Badie
JBJoan-Francesc Barquinero
Joan-Francesc Barquinero
AWAndrzej Wojcik
Andrzej Wojcik
Purpose: A European network was initiated in 2012 by 23 partners from 16 European countries with the aim to significantly increase individualized dose reconstruction in case of large-scale radiological emergency scenarios. Results: The network was built on three complementary pillars: (1) an operational basis with seven biological and physical dosimetric assays in ready-to-use mode, (2) a basis for education, training and quality assurance, and (3) a basis for further network development regarding new techniques and members. Techniques for individual dose estimation based on biological samples and/or inert personalized devices as mobile phones or smart phones were optimized to support rapid categorization of many potential victims according to the received dose to the blood or personal devices. Communication and cross-border collaboration were also standardized. To assure long-term sustainability of the network, cooperation with national and international emergency preparedness organizations was initiated and links to radiation protection and research platforms have been developed. A legal framework, based on a Memorandum of Understanding, was established and signed by 27 organizations by the end of 2015. Conclusions: RENEB is a European Network of biological and physical-retrospective dosimetry, with the capacity and capability to perform large-scale rapid individualized dose estimation. Specialized to handle large numbers of samples, RENEB is able to contribute to radiological emergency preparedness and wider large-scale research projects.

20 July 2016 in International Journal of Radiation Biology
Verified
Journal Article
Open access
EAElizabeth Ainsbury
Elizabeth Ainsbury
Christophe BadieChristophe Badie
Christophe Badie
SBStephen Barnard
Stephen Barnard
GMGrainne Manning
Grainne Manning
JMJayne Moquet
Jayne Moquet
CWClemens Woda
Clemens Woda
Purpose: RENEB, ‘Realising the European Network of Biodosimetry and Physical Retrospective Dosimetry,’ is a network for research and emergency response mutual assistance in biodosimetry within the EU. Within this extremely active network, a number of new dosimetry methods have recently been proposed or developed. There is a requirement to test and/or validate these candidate techniques and inter-comparison exercises are a well-established method for such validation. Materials and methods: The authors present details of inter-comparisons of four such new methods: dicentric chromosome analysis including telomere and centromere staining; the gene expression assay carried out in whole blood; Raman spectroscopy on blood lymphocytes, and detection of radiation-induced thermoluminescent signals in glass screens taken from mobile phones. Results: In general the results show good agreement between the laboratories and methods within the expected levels of uncertainty, and thus demonstrate that there is a lot of potential for each of the candidate techniques. Conclusions: Further work is required before the new methods can be included within the suite of reliable dosimetry methods for use by RENEB partners and others in routine and emergency response scenarios.